Takeda Signs an Exclusive License Agreement with Poseida for Novel Non-Viral In Vivo Gene Therapies
Shots:
- The parties will initially develop up to 6 in vivo gene therapy programs utilizing Poseida's piggyBac- Cas-CLOVER & biodegradable nanoparticle technology for 6 liver & HSC directed indications. Takeda has an option to add 2 additional programs and is obligated to provide funding for all program's R&D costs
- Poseida to receive $45M up front & preclinical milestones exceeding $125M- if milestones for 6 programs are achieved. The company is also eligible for ~2.7B milestones for all 6 programs and ~$3.6B if the milestones related to the 2 optional programs are also achieved
- Poseida will lead research activities up to candidate selection- after which Takeda will lead development & commercialization
| Ref: PR Newswire | Image: Poseida
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com